Ocuphire Announces Financial Results for First Quarter 2023
Ocuphire Pharma has announced in a press release financial results for the first quarter ended March 31, 2023, and provided a corporate update. Key anticipated milestones include topline results expected from the VEGA-2 phase 3 pivotal trial of Nyxol in presbyopia in late 2023, and a PDUFA date (September 28, 2023) for Nyxol in reversal of pharmacologically-induced mydriasis. FDA approval for that indication would trigger a $10 million milestone payment to Ocuphire. As of March 31, 2023, Ocuphire had cash and cash equivalents of approximately $39.0 million. The company has no debt. Based on current projections, management believes the present cash on hand will be sufficient to fund operations into 2025. The release said Nyxol clinical programs in presbyopia and dim light disturbances continue to progress as planned. More information can be found at https://www.ocuphire.com/news-media/press-releases/detail/403/ocuphire-pharma-announces-financial-results-for-first.
Visus Therapeutics Presents at 2023 JMP Securities Life Science Conference
Visus Therapeutics announced that Ben Bergo, co-founder and CEO, would present at the JMP Securities Life Science Conference in New York. The company has announced positive topline clinical data from the Phase 3 pivotal BRIO-I trial of BRIMOCHOL PF for the treatment of presbyopia. BRIMOCHOL PF met its prespecified FDA primary endpoint for binocular near visual acuity across multiple time points, starting at hour 1, versus active controls, and was well tolerated with no significant adverse events. More information can be found at https://www.businesswire.com/news/home/20230512005175/en/Visus-Therapeutics-to-Present-at-2023-JMP-Securities-Life-Science-Conference.
Study Evaluates Range of Vision for Clareon Monofocal IOLs and TECNIS Eyhance Monofocal IOLs
Alcon has announced results from a new study the company says demonstrated Clareon (Alcon) and Eyhance (Johnson & Johnson Vision) monofocal IOLs provide a similar range of vision, including distance and intermediate visual acuity. In a press release the company said the study evaluated 620 eyes of 310 patients (155 Clareon and 155 Eyhance) who had undergone successful, uncomplicated cataract surgery at least three months prior and had post-operative best-corrected distance visual acuity of 20/25 or better after cataract removal. According to the release, the results showed best-corrected distance acuity in eyes implanted with Clareon (0.01 logMAR) was similar to best-corrected distance acuity with Eyhance (0.02 logMAR), distance-corrected intermediate acuity was similar in both groups with only a 2.5 letter mean difference, and the binocular defocus curves were extremely similar from +1.00D to -3.00D. More information can be found at https://www.businesswire.com/news/home/20230505005465/en/New-Head-to-Head-Data-Show-Clareon-Monofocal-IOLs-and-TECNIS-Eyhance-Monofocal-IOLs-Provide-Similar-Range-of-Vision.
Article Reports on Clinical Outcomes of a Four-haptic Hydrophobic PC-IOL
An article published in Scientific Reports gives outcomes from a study on the Artis Symbiose Plus (Cristalens) presbyopia-correcting intraocular lens, which combines bifocal and extended-depth-of-focus profiles. The study compared the performance of this lens with that of a monofocal Artis PL E (PL E; Cristalens) IOL on the same platform. The authors concluded that the comparison showed the Symbiose lens provides a continuous range of vision that ensures a seamless transition from far to near with no discontinuity. It also delivers a smooth defocus curve with a larger landing area than the PL E. But the objective optical quality was better in the PL E. More information can be found at https://www.nature.com/articles/s41598-023-35377-0.